Clinical Trial Update: A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial investigating SHR-1210 with carboplatin and paclitaxel-albumin in resectable non-small cell lung cancer; status is currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• SHR-1210 (camrelizumab)
• paclitaxel-albumin (paclitaxel-albumin)

Snippet

Sponsor: Xuanwu Hospital, Beijing | Conditions: Lung Cancer Stage II, PD-1 Antibody | Phase 2 | Status: UNKNOWN